Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
9 hedge funds and large institutions have $182K invested in Plus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.03% less ownership
Funds ownership: 0.12% → 0.09% (-0.03%)
18% less funds holding
Funds holding: 11 → 9 (-2)
27% less capital invested
Capital invested by funds: $247K → $182K (-$65.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.29K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$30.2K |
| 2 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$25.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$15.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$11.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $58.7K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $52.8K | +$5.27K | +109 | +10% |
|
|
3
Renaissance Technologies
New York
| $31K | -$30.2K | -624 | -47% |
|
|
4
Citadel Advisors
Miami,
Florida
| $19.3K | -$11.9K | -246 | -36% |
|
5
BlackRock
New York
| $12.6K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $6.91K | +$6.29K | +130 | +565% |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $240 | – | – | – |
|
8
JP Morgan Chase
New York
| $181 | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $63 | – | – | – |
|
10
Group One Trading
Chicago,
Illinois
| $2 | – | – | – |
|
|
GSC
11
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$25.6K | -572 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$15.6K | -356 | Closed |
|
PSTV Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2024, worth a combined $182K — down 27% from $247K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PSTV and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $6.29K. The largest seller was Renaissance Technologies, cutting an estimated $30.2K.
- 9 institutional investors held Plus Therapeutics (PSTV) as of Q1 2024, down from 11 in Q4 2023.
- Funds reported $182K of Plus Therapeutics stock for Q1 2024, down 27% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q1 2024 and 2 closed out, a net change of -2 holders.
- The largest Plus Therapeutics buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $6.29K added.
- The largest Plus Therapeutics seller in Q1 2024 was Renaissance Technologies, an estimated $30.2K sold.
Based on aggregated 13F filings for Q1 2024.